Ken Griffin Invitae Corp Call Options Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Feb 14, 2024	BUY	$0.42 - $0.72 $63,420 - $108,720	151,000 Added 61.16%	397,900 $250,000
Q3 2023 Nov 14, 2023	SELL	$0.6 - $1.53 $30,120 - $76,806	-50,200 Reduced 16.9%	246,900 $148,000
Q2 2023 Aug 14, 2023	BUY	$1.05 - $1.63 $21,525 - $33,415	20,500 Added 7.41%	297,100 $335,000
Q1 2023 May 15, 2023	SELL	$1.2 - $2.73 $228,240 - $519,246	-190,200 Reduced 40.75%	276,600 $373,000
Q4 2022 Feb 14, 2023	BUY	$1.71 - $3.61 $5,301 - $11,191	3,100 Added 0.67%	466,800 $868,000
Q3 2022 Nov 14, 2022	BUY	$1.9 - $8.63 $96,710 - $439,267	50,900 Added 12.33%	463,700 $1.14 Million

1.92M

Ticker NVTA
Exchange NYSE
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 235,266,000
Description
Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.